Wall Street brokerages expect Trevena Inc (NASDAQ:TRVN) to announce earnings per share of ($0.26) for the current quarter, according to Zacks. Zero analysts have made estimates for Trevena’s earnings. The highest EPS estimate is ($0.24) and the lowest is ($0.27). Trevena reported earnings per share of ($0.67) during the same quarter last year, which would suggest a positive year over year growth rate of 61.2%. The business is expected to issue its next quarterly earnings results on Wednesday, March 14th.
On average, analysts expect that Trevena will report full-year earnings of ($1.23) per share for the current financial year, with EPS estimates ranging from ($1.25) to ($1.21). For the next year, analysts expect that the business will report earnings of ($0.97) per share, with EPS estimates ranging from ($1.17) to ($0.82). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Trevena.
Trevena (NASDAQ:TRVN) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.06. During the same quarter in the prior year, the firm earned ($0.57) earnings per share.
Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Trevena by 15.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,822,103 shares of the biopharmaceutical company’s stock valued at $4,191,000 after buying an additional 238,089 shares in the last quarter. Northpointe Capital LLC boosted its holdings in shares of Trevena by 5.0% in the 3rd quarter. Northpointe Capital LLC now owns 1,283,025 shares of the biopharmaceutical company’s stock valued at $3,272,000 after buying an additional 61,546 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Trevena by 37.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 980,440 shares of the biopharmaceutical company’s stock valued at $2,500,000 after buying an additional 268,825 shares in the last quarter. State Street Corp boosted its holdings in shares of Trevena by 8.3% in the 2nd quarter. State Street Corp now owns 768,249 shares of the biopharmaceutical company’s stock valued at $1,767,000 after buying an additional 58,895 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Trevena by 15.8% in the 2nd quarter. Northern Trust Corp now owns 572,662 shares of the biopharmaceutical company’s stock valued at $1,318,000 after buying an additional 77,934 shares in the last quarter. Institutional investors and hedge funds own 56.10% of the company’s stock.
Trevena (TRVN) opened at $1.75 on Friday. The company has a quick ratio of 4.92, a current ratio of 4.92 and a debt-to-equity ratio of 0.38. Trevena has a 1-year low of $1.35 and a 1-year high of $8.00. The company has a market cap of $109.03, a PE ratio of -1.06 and a beta of -0.58.
TRADEMARK VIOLATION WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/21/0-26-earnings-per-share-expected-for-trevena-inc-trvn-this-quarter.html.
Trevena Company Profile
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.